Retifanlimab联合卡铂和紫imToken官网杉醇治疗局部复发或转移

double-blind， Laetitia Dahan， time from date of randomisation to date of first documented progressive disease or death due to any cause) per Response Evaluation Criteria in Solid Tumours version 1.1. Efficacy was assessed by intention to treat. This trial is registered with ClinicalTrials.gov (NCT04472429) and EUDRA-CT (202000082624) and is active but closed to enrolment. Findings